GLOW Protocol
A combination protocol pairing BPC-157, TB-500 (thymosin beta-4 fragment) and the copper peptide GHK-Cu, marketed for skin, hair and connective-tissue recovery.
Evidence-led profile
Research snapshot
- Evidence stage
- Emerging research
- References
- 5 linked sources
- Editorial review
- Jul 7, 2026
Published by the PepGuide Editorial Team using our research methodology.
Overview
The 'GLOW' protocol is a blend popular in wellness and aesthetic peptide circles, combining three separately researched compounds:
- BPC-157 -- a synthetic pentadecapeptide derived from a gastric protein that accelerates healing of tendon, ligament, muscle and gut tissue in animal models, in large part by promoting angiogenesis through VEGF upregulation (Chang et al., 2019; Brcic et al., 2009).
- TB-500 -- a synthetic fragment corresponding to the active region of thymosin beta-4, an actin-sequestering peptide that promotes cell migration, angiogenesis and wound repair (Philp et al., 2004).
- GHK-Cu -- the copper-binding tripeptide glycyl-L-histidyl-L-lysine, which drives tissue remodeling by stimulating collagen, elastin and glycosaminoglycan synthesis and supporting dermal fibroblasts (Pickart, 2008; Pickart et al., 2018).
The design rationale is mechanistic complementarity: BPC-157 and TB-500 both drive angiogenesis and cell migration needed for repair, while GHK-Cu supplies the matrix-building and skin-remodeling signal that gives the protocol its cosmetic 'glow' reputation.
Typical stack dosing (research-community practice, not clinically validated): commonly a once-daily subcutaneous injection providing roughly BPC-157 250-500 mcg, TB-500 250-500 mcg, and GHK-Cu 1-2 mg, often run in cycles of several weeks. These amounts are extrapolated from the component peptides' preclinical literature and community protocols rather than from trials of the blend; none of these peptides is FDA-approved, and human safety/efficacy data for the combination are lacking.
Safety and Limitations
Safety Profile: Glow Protocol
Common Side Effects
- Side effects depend on the specific components included in the protocol formulation
- Mild gastrointestinal upset (nausea, bloating) from combined oral supplements
- Skin flushing or warmth, particularly with niacin-containing variants
- Headache during initial adaptation period
- Mild changes in urination patterns depending on ingredients
Serious Adverse Effects
- Potential for adverse interactions between multiple active compounds in the blend
- Allergic reactions to any component ingredient (rash, angioedema, anaphylaxis in rare cases)
- Liver or kidney stress from polypharmacy if protocol includes multiple hepatically metabolized compounds
- Hormonal disruption if protocol includes endocrine-active peptides or compounds
Contraindications
- Known allergy or hypersensitivity to any component of the protocol
- Pregnancy and lactation (insufficient safety data for combination protocols)
- Active liver or kidney disease
- Individuals currently on immunosuppressive therapy
- Minors under 18 years of age
Drug Interactions
- Interactions are component-dependent; review each individual ingredient
- Combined antioxidant blends may interfere with chemotherapy or radiation therapy
- Compounds with anticoagulant properties may potentiate blood thinners
- Potential for CYP450 enzyme modulation affecting prescription drug metabolism
- Supplements affecting blood glucose may interact with diabetes medications
Population-Specific Considerations
- Pregnancy/Lactation: Contraindicated due to lack of safety data on combined formulation
- Children/Adolescents: Not recommended; safety and efficacy not established
- Elderly: Start with reduced component doses; monitor organ function regularly
- Immunocompromised: Use with extreme caution; consult healthcare provider
- Chronic disease: Consult physician before starting any multi-compound protocol
Mechanism of Action
The angiogenic and migratory actions of BPC-157 and TB-500 are complementary: BPC-157 works largely through the VEGFR2-Akt-eNOS/nitric-oxide axis to modulate blood-vessel formation during healing, while thymosin beta-4's LKKTET actin-binding domain drives endothelial and progenitor-cell migration. GHK-Cu then supplies the remodeling signal, increasing dermal fibroblast collagen/elastin output and supporting nerve and vessel outgrowth. The combined effect proposed by the protocol is faster tissue repair with improved skin and connective-tissue quality, though this synergy is inferred from single-agent data.
References (5)
- [1]Chang CH, Tsai WC, Hsu YH, Pang JS Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing International Journal of Molecular Sciences (2019)
→ Review of BPC-157's preclinical role in accelerating healing of tendon, ligament and muscle soft tissue.
- [2]Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing Journal of Physiology and Pharmacology (2009)
→ BPC-157 promotes angiogenesis during muscle and tendon healing via upregulation of VEGF expression.
- [3]Philp D, Goldstein AL, Kleinman HK Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development Mechanisms of Ageing and Development (2004)
→ Thymosin beta-4 (the parent of TB-500) promotes angiogenesis, cell migration and wound repair in normal and aged animals.
- [4]Pickart L The human tri-peptide GHK and tissue remodeling Journal of Biomaterials Science, Polymer Edition (2008)
→ GHK-Cu supports tissue remodeling, stimulating collagen, elastin and glycosaminoglycan synthesis while modulating inflammation.
- [5]Pickart L, Vasquez-Soltero JM, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data International Journal of Molecular Sciences (2018)
→ GHK-Cu stimulates blood vessel and nerve outgrowth and increases collagen/elastin synthesis, with gene-expression data supporting broad regenerative actions.
Continue researching GLOW Protocol
Keep scientific evidence separate from commercial availability. Review how claims are evaluated, explore question-led research paths, or inspect disclosed source records without changing the editorial conclusions on this page.